

Sheet 1 of 4

Subst. Form PTO-1449			Docket Number (Optional) 40567	Application Number 09/610,891		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant MCARTHUR et al.			
(Use several sheets if necessary)			Filing Date 6 July 2001	Group Art Unit 1643		
U. S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,631,275	06/05/90	Shimizky et al.	424	88	
	5,078,990	01/07/92	Cotton, III et al.	424	85.1	
	5,098,702	03/24/92	Zimmerman et al.	424	85.21	
	5,674,486	10/07/97	Sobol et al.	424	93.21	
	5,763,155	06/09/98	Boon-Falleur et al.	435	4	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Darrow, Timothy J. et al., 1989 The Journal of Immunology, Vol. 142, No. 9, "The Role of HLA Class I Antigens in Recognition of Melanoma Cells by Tumor-Specific Cytotoxic T Lymphocytes" pp 3329-3335.					
	Crowley, Nancy J. et al., 1991 The Journal of Immunology, Vol. 146, No. 5, "MHC-Restricted Recognition of Autologous Melanoma by Tumor-Specific Cytotoxic Cells" pp. 1692-1699					
	Crowley, Nancy J. et al., 1992 CANCER RESEARCH 52, "Human Xenograft-Nude Mouse Model of Adoptive Immunotherapy with Human Melanoma-specific Cytotoxic T-Cells", pp. 394-399.					
EXAMINER	Notable Dev			DATE CONSIDERED 8/20/00		
EXAMINER: Initial if citation considered. Whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.						

Sheet 2 of 4

Subst. Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		Docket Number (Optional)  40567	Application Number  09/610,891
		Applicant  MCARTHUR et al.	
		Filing Date  6 July 2001	Group Art Unit  1643
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<p>Beldzegrum, Ari et al., 1998 CANCER RESEARCH 48, "Interleukin 2 Expanded Tumor-infiltrating Lymphocytes In Human Renal Cell Cancer: Isolation, Characterization, and Antitumor Activity" pp.206-214</p> <p>Ikemoto, Shinichi et al., 1992 Cancer Immunology Immunotherapy 34, "Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-<math>\gamma</math> production of lymphocytes", pp. 289-293</p> <p>Urban, James L. et al., 1992 Annu. Rev. Immunol. 10, "Tumor Antigens", pp. 617-644</p> <p>van der Bruggen, P. et al., 1991 Science 254, "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma", pp. 1643-1647</p> <p>Sanda, Martin G. et al., 1994 The Journal of Urology Vol. 151, "Demonstration of a Rational Strategy for Human Prostate Cancer Gene Therapy", pp. 622-628.</p> <p>Asher, A.L. et al., 1991 The Journal of Immunology Vol. 146, "Murine Tumor Cells Transduced with the Gene for Tumor Necrosis Factor-<math>\alpha</math>", pp. 3227-3234.</p> <p>Havell, Edward A. et al., 1988 J. Exp. Med. Vol. 167, "The Antitumor function of Tumor Necrosis Factor (TNF)", pp. 1067-1085.</p> <p>Gansbacher, Bernd et al., 1990 CANCER RESEARCH 50, "Retroviral Vector-mediated <math>\gamma</math>-Interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity", pp. 7829-7835.</p> <p>Ley, Victoria et al., 1991 Eur. J. Immunol. 21, "Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes <i>in vivo</i>", pp. 851-854</p> <p>Watanabe, Yoshihiko et al., 1989 Proc. Natl. Acad. Sci. USA, Vol. 86, "Exogenous expression of mouse interferon <math>\gamma</math> rDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity", pp. 9456-9460.</p> <p>Gansbacher, Bernd et al., 1990 J. Exp. Med. Vol. 172, "Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity", pp. 1217-1224.</p> <p>Gansbacher, Bernd et al., 1992 Proceedings of the American Association for Cancer Research, Vol. 33, "Retroviral factors carrying both the IL-2 and the IFN-gamma gene induce potent anti-tumor response in murine tumors", p. 351.</p> <p>Tepper, Robert I. et al., 1989 Cell Vol. 57, "Murine Interleukin-4 Displays Potent Anti-Tumor Activity <i>in Vivo</i>", pp. 503-512.</p> <p>Porgador, Angel et al., 1992 CANCER RESEARCH 52, "Interleukin 6 Gene Transfection into Lewis Lung Carcinoma Tumor Cells Suppresses the Malignant Phenotype and Confers Immunotherapeutic Competence against Parental Metastatic Cells", pp. 3679-3686.</p> <p>Formi, Guido et al., 1988 Cancer and Metastasis Reviews 7, "Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy", pp. 289-309.</p> <p>Fearon, Eric R. et al., 1990 Cell Vol. 60, "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response", pp. 397-403.</p>			
EXAMINER  <i>Notre Dame</i>	DATE CONSIDERED  <i>8/20/01</i>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.			

Sheet 3 of 4

Subst. Form PTO-1449		Docket Number (Optional) 40567	Application Number 09/610,891
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant MCARTHUR et al.	
		Filing Date 6 July 2000	Group Art Unit 1643

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Amico, M.D., Salvatore et al., 1991 CLINICAL NUCLEAR MEDICINE Vol. 16, "Comparison of Phosphatase Isoenzymes PAP and PSA with Bone Scan in Patients with Prostate Carcinoma", p. 643-648.
	Gerber, M.D., Glen et al., 1991 UROLOGY Vol. 37, No. 5, "Assessment of Value of Routine Bone Scans in Patients with Newly Diagnosed Prostate Cancer", pp. 418-422.
	Borrello, Ivan et al., 1999 HUMAN GENE THERAPY 10, "A Universal Granulocyte-Macrophage Colony-Stimulating Factor-Producing Bystander Cell Line for Use in the Formulation of Autologous tumor Cell-Based Vaccines", pp. 1983-1991.
	Pechl, Donna M., "The Male Reproductive System: Prostatic Cell Lines", Atlas of Human Tumor Cell Lines, Academic Press, Inc., 1994, pp. 387-407.
	Hock, Hanno et al., 1991 J. Exp. Med. Vol. 174, "Interleukin 7 Induces CD4+ T Cell-dependent Tumor Rejection", pp. 1291-1298.
	Pardoll, Drew M. et al., 1993 Current Opinion in Immunology 5, "New strategies for enhancing the immunogenicity of tumors", pp. 719-725.
	Nelson, Ph.D., William G. et al., 1996 THE UROLOGIC CLINICS OF NORTH AMERICA Vol. 23, No. 4, "New Approaches to Adjuvant Therapy for Patients with Adverse Histopathologic Findings Following Radical Prostatectomy", pp. 655-656.
	Dranoff, Glen et al., 1993 Proc. Natl. Acad. Sci. USA, "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", pp. 3539-3543.
	Porgador, Angi et al., 1994 Nat. Immun. 13, "Immunotherapy of Tumor Metastasis via Gene Therapy", pp. 113-130.
	Radizzani, Marina et al., 1989 Cancer Immunol. Immunother. 28, "Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor-target cells", pp. 67-73.
	Beildegrun, Aris et al., 1990 Cancer Immunol. Immunother. 31, "Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid", pp. 1-10.
	Kee, A.S. et al., 1991 Journal of Immunotherapy 10, "Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma", pp. 347-354.
	Devita et al., eds., "Chapter 4: Biology of Cytokines: The Interleukins", "Chapter 5: Principles of Cell Killing by Biologic Agents", "Chapter 6: Principles of Tumor Immunity: Immunocompetence and Cancer", Biological Therapy of Cancer, 5 Lippincott Co., 1991; pp. 87-118.
	Jennides et al., 1993 Immunol. 37, pp. 413-442
	Harlow et al., eds. Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratories, 1988, pp. 61-67.
	Alexander et al., 1990 J. Cancer 45; p. 119.

EXAMINER

*Not done DPe*

DATE CONSIDERED

*8/20/01*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

Sheet 4 of 4

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.